Skip to main content
AmigoFish

Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho

From Business Of Biotech · · 55 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new)

On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/).

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Back to Business Of Biotech · Report a problem